EyePoint, Inc. (EYPT)
4.58
+0.02
(+0.33%)
USD |
NASDAQ |
Sep 04, 16:00
4.575
0.00 (0.00%)
After-Hours: 20:00
EyePoint Research and Development Expense (Quarterly) : 83.61M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 83.61M |
| March 31, 2026 | 72.15M |
| December 31, 2025 | 59.21M |
| September 30, 2025 | 47.75M |
| June 30, 2025 | 55.50M |
| March 31, 2025 | 58.57M |
| December 31, 2024 | 43.37M |
| September 30, 2024 | 29.54M |
| June 30, 2024 | 29.82M |
| March 31, 2024 | 30.14M |
| December 31, 2023 | 17.95M |
| September 30, 2023 | 17.36M |
| June 30, 2023 | 15.73M |
| March 31, 2023 | 13.62M |
| December 31, 2022 | 15.54M |
| September 30, 2022 | 11.16M |
| June 30, 2022 | 12.99M |
| March 31, 2022 | 9.945M |
| December 31, 2021 | 8.918M |
| September 30, 2021 | 8.498M |
| June 30, 2021 | 5.605M |
| March 31, 2021 | 5.479M |
| December 31, 2020 | 5.205M |
| September 30, 2020 | 4.09M |
| June 30, 2020 | 3.276M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.853M |
| December 31, 2019 | 4.132M |
| September 30, 2019 | 3.484M |
| June 30, 2019 | 3.955M |
| March 31, 2019 | 3.797M |
| December 31, 2018 | 4.179M |
| September 30, 2018 | 6.233M |
| June 30, 2018 | 4.765M |
| March 31, 2018 | 3.325M |
| June 30, 2017 | 4.213M |
| March 31, 2017 | 3.324M |
| December 31, 2016 | 3.165M |
| September 30, 2016 | 4.178M |
| June 30, 2016 | 4.104M |
| March 31, 2016 | 3.112M |
| December 31, 2015 | 3.539M |
| September 30, 2015 | 3.306M |
| June 30, 2015 | 2.974M |
| March 31, 2015 | 3.339M |
| December 31, 2014 | 2.767M |
| September 30, 2014 | 2.784M |
| June 30, 2014 | 2.306M |
| March 31, 2014 | 2.269M |
| December 31, 2013 | 2.494M |
| September 30, 2013 | 2.504M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Ocular Therapeutix, Inc. | 54.14M |
| Eli Lilly & Co. | 3.819B |
| Elanco Animal Health, Inc. | 92.00M |
| Amylyx Pharmaceuticals, Inc. | 23.72M |
| Nuvation Bio, Inc. | 30.66M |